日本の核医学市場-2024～2031年

概要

日本の核医学市場は、2023年に5億5,030万米ドルに達し、2031年には25億4,320万米ドルに達すると予測され、予測期間2024-2031年のCAGRは21.2%で成長します。

核医学は、放射性医薬品として知られる放射性トレーサーを利用して身体機能を評価し、病気の診断や治療を行う医学の専門分野です。特殊なイメージングカメラにより、医師は体内の放射性トレーサーの動きをモニターすることができます。核医学で最も普及している2つのイメージング技術は、単一光子放射断層撮影法（SPECT）と陽電子放射断層撮影法（PET）スキャンです。

SPECTイメージング装置は、患者の体内に導入された放射性トレーサー分子の分布を示す3次元（断層）画像を生成します。これらの3D画像は、体内の様々な角度から撮影された多数の投影画像をコンピュータ処理することによって作成されます。SPECT画像装置には、患者に投与されたトレーサーからのガンマ線放射を識別できるガンマカメラ検出器が装備されています。

PETスキャンも放射性医薬品を利用して3次元画像を生成します。SPECT検査とPET検査の主な違いは、使用される放射性トレーサーの種類にあります。SPECT検査はガンマ線を検出するのに対し、PET検査で使用される放射性医薬品は崩壊時に陽電子と呼ばれる小さな粒子を発生させる。陽電子は電子と似た質量を持つが、反対の電荷を持つ粒子です。これらの要因が日本の核医学市場拡大の原動力となっています。

市場力学：

促進要因と阻害要因

がんと心臓疾患の有病率の増加

がんと心疾患の有病率の増加は、日本の核医学市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予想されます。

がんと心血管疾患の罹患率の増加は、核医学市場の成長の重要な触媒となっています。これらの健康状態がより広範になるにつれ、効果的な診断および治療オプションに対する需要が高まっています。核医学イメージング技術、特に陽電子放出断層撮影法（PET）と単一光子放出コンピュータ断層撮影法（SPECT）は、これらの疾患の早期発見と治療計画において重要な役割を果たしています。

日本は世界でも有数の長寿国です。20世紀半ば以降、伝染性疾患による死亡率が低下したことに続いて平均寿命が改善したのは、さまざまな要因によるものです。これには、国民皆保険によって利用しやすくなった高度な医療技術、定期的な健康診断や心血管疾患やがんの検診といった公衆衛生上の取り組み、健康的なライフスタイルに沿った伝統的な食生活の遵守などが含まれます。

しかし、心血管疾患とがんがもたらす課題は依然として重大であり、日本では増加傾向にあります。これらの疾患に対する患者の長期予後は顕著に改善しているにもかかわらず、がんは依然として死亡原因の第1位であり、心血管系疾患がこれに僅差で続いています。さらに、これらの疾患の罹患率は、特に高齢者の間で増加しており、患者や生存者の臨床転帰やQOLに影響を及ぼす可能性のある、がん治療に起因する心血管合併症に対する懸念を高めています。

がん治療の進展に伴い、核医学市場では、がん治療およびがん治療以外のさまざまな用途に取り組むための標的放射性医薬品（TRP）が重視されるようになっています。TRPは、標的分子、リンカー、キレート剤、放射性核種を含む複数の成分から構成される先進的な治療薬であり、これらが連携して、特定の分子標的を発現する細胞に直接、集中的な治療を行う。

2022年のWHOのデータによると、日本ではがんの統計から、新規患者数1,005,157人、死亡者数426,278人、有病者数2,741,718人（過去5年間）という公衆衛生上の重大な課題が明らかになっています。先進核医学ソリューションの需要が高まる中、この市場の利害関係者は、これらの緊急ヘルスケアニーズに効果的に対処するため、技術革新、調査、協力を優先しなければならないです。

さらに、提携や協力といった主要企業の戦略が日本の核医学市場を牽引すると思われます。例えば、国際原子力機関（IAEA）は2023年3月、「希望の光（Rays of Hope）」イニシアチブの一環として、日本の大学および科学機関からなる11のコンソーシアムと契約を締結しました。このイニシアチブは、アジア太平洋全域で核医学の労働力を強化し、同地域で高まるがん治療の改善ニーズに対応することを目的としています。

また2023年3月には、核医学に特化した日本の新興企業であるアドバンスト・メディカル・サイエンス・プランニング（AMS）が、京都大学との共同研究イニシアチブを発表しました。この提携は、ソマトスタチン受容体を標的とする放射性医薬品であるガリウム-68ドタトック（68Ga-DOTATOC）を日本のヘルスケア市場に導入することを目的としています。これらすべての要因が日本の核医学市場を需要しています。

さらに、標的放射性医薬品の市場開発に対する需要の高まりも、日本の核医学市場の拡大に寄与しています。

高い放射性医薬品コスト

画像診断や治療技術を含む核医学処置に関連する高額な費用は、患者の利用しやすさに大きな障壁となっています。核医学治療には、高度なイメージング装置（PETやSPECT装置など）、放射性医薬品の製造・入手、専門施設の運営費など、さまざまなコストがかかります。これらの処置にかかる費用は、その複雑さや種類によって、数百ドルから数千ドルの幅があります。このような価格設定のばらつきは、必要な診断検査や治療を受けようとする患者の意欲を削ぐことになりかねないです。

画像診断装置、放射線装置、核医学装置の平均価格は5万8,657米ドルと報告されています。この数字は、医療診断に使用される様々な種類の画像診断技術の取得に関連する一般的な費用を反映しています。

高額な費用は、特に低所得者やヘルスケア資源が限られている地域の患者のアクセスを制限する可能性があります。多くの患者は、自己負担額をまかなうのに苦労したり、核医学検査に十分な保険が適用されなかったりするため、重要な診断・治療サービスへのアクセスが不公平になります。

核医学検査はMRIやCT検査など他の画像診断法と競合することが多く、費用がかかるにもかかわらず、より手ごろな選択肢として認識されることがあります。さらに、放射線を使用しない画像診断法はより安全であるという考え方は、特にコストに敏感な人々の間で、核医学サービスに対する需要をさらに低下させる可能性があります。したがって、上記の要因が日本の核医学市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • がんや心臓疾患の罹患率の増加と
  • 抑制要因
    • 放射性医薬品の高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 製品タイプ別

• 一般および診断機器
• 診断
  • 単一光子放出コンピュータ断層撮影（SPECT）
  • テクネチウム-99m（Tc-99m）
  • タリウム-201（Tl-201）
  • ガリウム67（Ga-67）
  • ヨウ素123（I-123）
  • その他
  • 陽電子放出断層撮影（PET）
  • フッ素-18（F-18）
  • ルビジウム82（Rb-82）
  • その他
• 治療薬
  • アルファ放射体
  • ラジウム-223（Ra-223）
  • その他
  • ベータ放射体
  • ヨウ素131（I-131）
  • イットリウム90（Y-90）
  • ルテチウム-177（Lu-177）
  • その他
  • 近接放射線治療同位元素
  • セシウム131
  • ヨウ素125
  • パラジウム103
  • イリジウム192
  • その他

第7章 手順量の評価別

• 診断手順
  • SPECT手順
  • PET手順
• 治療手順

第8章 用途別

• 心臓病学
• 腫瘍学
• 神経学
• 甲状腺疾患
• 内分泌腫瘍
• リンパ腫と骨転移
• 肺スキャン
• 泌尿器科
• その他

第9章 エンドユーザー別

• 病院
• 診断センター
• その他

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• GE Healthcare
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Fujifilm（FUJIFILM Toyama Chemical Co. Ltd）
• Siemens Healthineers
• Bracco
• CANON MEDICAL SYSTEMS CORPORATION
• Nihon Medi-Physics Co.（Sumitomo Chemical Co. Ltd）
• ATOX CO., Ltd.
• IBA Radiopharma Solutions
• JFE Engineering Corporation
• Koninklijke Philips N.V.

第12章 付録

Overview

The Japan nuclear medicine market reached US$ 550.3 million in 2023 and is expected to reach US$ 2,543.2 million by 2031, growing at a CAGR of 21.2 % during the forecast period 2024-2031.

Nuclear medicine is a medical specialty that utilizes radioactive tracers, known as radiopharmaceuticals, to evaluate bodily functions and diagnose or treat diseases. Specialized imaging cameras enable physicians to monitor the movement of these radioactive tracers within the body. The two most prevalent imaging techniques in nuclear medicine are Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) scans.

SPECT imaging devices generate three-dimensional (tomographic) images showing the distribution of radioactive tracer molecules introduced into a patient's body. These 3D images are created by computer processing a multitude of projection images captured from various angles around the body. SPECT imagers are equipped with gamma camera detectors that can identify the gamma-ray emissions from the tracers that have been administered to the patient.

PET scans also utilize radiopharmaceuticals to generate three-dimensional images. The primary distinction between SPECT and PET scans lies in the types of radiotracers employed. SPECT scans detect gamma rays, whereas the radiotracers used in PET scans produce small particles known as positrons upon decay. A positron is a particle that has a mass similar to that of an electron but carries an opposite charge. These factors have driven Japan nuclear medicine market expansion.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Cancer and Cardiac Disorders

The increasing prevalence of cancer and cardiac disorders is significantly driving the growth of the Japan nuclear medicine market and is expected to drive throughout the market forecast period.

The increasing incidence of cancer and cardiovascular diseases serves as a significant catalyst for the groth of the nuclear medicine market. As these health conditions become more widespread, there is a rising demand for effective diagnostic and therapeutic options. Nuclear imaging techniques, particularly Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) play a crucial role in the early detection and treatment planning for these diseases.

Japan boasts one of the highest life expectancies globally. The improvement in life expectancy since the mid-20th century, following a decline in mortality from communicable diseases, can be attributed to various factors. These include advanced medical technologies that are accessible due to universal health insurance, public health initiatives like routine health check-ups and screenings for cardiovascular diseases and cancer, and adherence to a traditional diet along with a healthy lifestyle.

However, the challenges posed by cardiovascular diseases and cancer remain significant and are on the rise in Japan. Despite notable improvements in long-term patient outcomes for these conditions, cancer continues to be the leading cause of death, followed closely by cardiovascular diseases. Furthermore, the incidence of these diseases is increasing, particularly among the aging population, raising concerns about cardiovascular complications resulting from cancer treatments that can affect clinical outcomes and quality of life for patients and survivors.

As cancer treatment progresses, the nuclear medicine market is placing greater emphasis on targeted radiopharmaceuticals (TRPs) to tackle a range of oncology and non-oncology applications. TRPs are advanced therapeutic agents that consist of multiple components, including a targeting molecule, linker, chelating agent, and radionuclide, which work together to deliver focused treatment directly to cells that express specific molecular targets.

According to the WHO data in 2022, in Japan, the cancer statistics reveal a significant public health challenge, with 1,005,157 new cases, 426,278 deaths, and 2,741,718 prevalent cases (over the past five years). As the demand for advanced nuclear medicine solutions rises, stakeholders in this market must prioritize innovation, research, and collaboration to effectively address these urgent healthcare needs.

Furthermore, key player's strategies such as partnerships and collaborations would drive the Japan nuclear medicine market. For instance, in March 2023, the International Atomic Energy Agency (IAEA) recently signed an agreement with an 11-member consortium of universities and scientific institutions in Japan as part of its Rays of Hope initiative. This initiative aims to enhance the nuclear medicine workforce across Asia and the Pacific, addressing the growing need for improved cancer care in the region.

Also, in March 2023, Advanced Medical Science-Planning (AMS), a Japanese start-up focused on nuclear medicine, announced a collaborative research initiative with Kyoto University. This partnership aims to introduce Gallium-68 DOTATOC (68Ga-DOTATOC), a radiopharmaceutical that targets somatostatin receptors, into the Japanese healthcare market. All these factors demand the Japan nuclear medicine market.

Moreover, the rising demand for the development of targeted radiopharmaceuticals contributes to Japan nuclear medicine market expansion.

High Cost of Radiopharmaceuticals

The high costs associated with nuclear medicine procedures, including imaging and therapeutic techniques, present a significant barrier to patient accessibility. Nuclear medicine procedures incur various costs, such as those for advanced imaging equipment (like PET and SPECT machines), the production and acquisition of radiopharmaceuticals, and the operational expenses of specialized facilities. The costs for these procedures can range from several hundred to several thousand dollars, depending on their complexity and type. This variability in pricing can discourage patients from pursuing necessary diagnostic tests or treatments.

The average price of diagnostic imaging, radiology, and nuclear medicine equipment is reported to be $58,657. This figure reflects the general cost associated with acquiring various types of imaging technology used in medical diagnostics.

The elevated costs can restrict access for patients, particularly those from lower-income backgrounds or in areas with limited healthcare resources. Many patients may struggle to cover out-of-pocket expenses or may not have sufficient insurance coverage for nuclear medicine procedures, leading to inequities in access to vital diagnostic and therapeutic services.

Nuclear medicine often competes with other imaging techniques like MRI and CT scans, which might be perceived as more affordable options despite their costs. Additionally, the belief that non-radiation-based imaging methods are safer can further decrease demand for nuclear medicine services, especially among cost-sensitive populations. Thus, the above factors could be limiting the Japan nuclear medicine market's potential growth.

Segment Analysis

The Japan nuclear medicine market is segmented based on product type, procedural volume assessment, application, and end-user.

Product Type:

The diagnostics segment is expected to dominate the Japan nuclear medicine market share

The diagnostics segment holds a major portion of the Japan nuclear medicine market share and is expected to continue to hold a significant portion of the Japan nuclear medicine market share during the forecast period.

The diagnostics segment of the Japan nuclear medicine market is a vital area that includes various imaging techniques and radiopharmaceuticals essential for detecting and managing diseases, particularly cancer. This segment prominently features Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), both crucial for accurately identifying tumors, evaluating their progression, and formulating treatment plans.

For instance, F-18 PSMA-1007 PET has emerged as a cutting-edge diagnostic tool specifically designed to detect prostate cancer recurrence and metastasis with high precision. This imaging agent has demonstrated superior detection capabilities compared to traditional methods like CT and bone scintigraphy, underscoring its importance in oncology diagnostics.

Institutions such as St. Luke's MediLocus provide comprehensive PET-CT scan screenings aimed at early cancer detection. These screenings are critical since early diagnosis significantly enhances treatment outcomes. The integration of PET and CT in one system improves imaging quality, facilitating better visualization of tumors.

The ongoing development of new radiopharmaceuticals is expanding the diagnostic capabilities of nuclear medicine. Research into various PET and SPECT tracers is enhancing the visualization of tumor metabolism, receptor activity, and brain function, thereby broadening the scope of nuclear medicine applications.

Furthermore, key players in the country strategies such as partnerships and collaborations would drive this segment growth in the Japan nuclear medicine market. For instance, in October 2024, Curium announced a strategic partnership with PDRadiopharma Inc., a wholly-owned subsidiary of PeptiDream. This collaboration focuses on the clinical development, regulatory filing, and commercialization in Japan of two key radiopharmaceutical agents: 177Lu-PSMA-I&T and 64Cu-PSMA-I&T.

Both agents are designed to target the prostate-specific membrane antigen (PSMA), which is expressed on prostate cancer cells, making them significant for both treatment and diagnostic purposes in prostate cancer management. These factors have solidified the segment's position in the Japan nuclear medicine market.

Competitive Landscape

The major players in the Japan nuclear medicine market include GE Healthcare, Fujifilm (FUJIFILM Toyama Chemical Co. Ltd), Siemens Healthineers, Bracco, CANON MEDICAL SYSTEMS CORPORATION, Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd), ATOX CO., Ltd., IBA Radiopharma Solutions, JFE Engineering Corporation, and Koninklijke Philips N.V. among others.

Key Developments

• In November 2024, Akio Ohta, a researcher from Chiyoda Technol Corporation (CTC) in Japan, stated that the company has been collaborating with the National Research and Innovation Agency (BRIN) on the development of extraction technology for Molybdenum-99 (Mo-99) and Technetium-99m (Tc-99m). This collaboration is facilitated through the Japan Atomic Energy Agency (JAEA), indicating a strategic partnership aimed at enhancing the production and availability of these critical isotopes used in nuclear medicine.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Japan nuclear medicine market report delivers a detailed analysis with 40+ key tables, more than 30 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Procedural Volume Assessment & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Procedural Volume Assessment
• 3.3. Snippet by Application
• 3.4. Snippet by End-User

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Cancer and Cardiac Disorders and
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Radiopharmaceuticals
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. General and Diagnostic Equipment*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Diagnostics
  • 6.3.1. Single Photon Emission Computed Tomography (SPECT)
  • 6.3.2. Technetium-99m (Tc-99m)
  • 6.3.3. Thallium-201 (Tl-201)
  • 6.3.4. Gallium-67 (Ga-67)
  • 6.3.5. Iodine-123 (I-123)
  • 6.3.6. Others
  • 6.3.7. Positron Emission Tomography (PET)
  • 6.3.8. Fluorine-18 (F-18)
  • 6.3.9. Rubidium-82 (Rb-82)
  • 6.3.10. Others
• 6.4. Therapeutics
  • 6.4.1. Alpha Emitters
  • 6.4.2. Radium-223 (Ra-223)
  • 6.4.3. Others
  • 6.4.4. Beta Emitters
  • 6.4.5. Iodine-131 (I-131)
  • 6.4.6. Yttrium-90 (Y-90)
  • 6.4.7. Lutetium-177 (Lu-177)
  • 6.4.8. Others
  • 6.4.9. Brachytherapy Isotopes
  • 6.4.10. Cesium-131
  • 6.4.11. Iodine-125
  • 6.4.12. Palladium-103
  • 6.4.13. Iridium-192
  • 6.4.14. Others

7. By Procedural Volume Assessment

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedural Volume Assessment
  • 7.1.2. Market Attractiveness Index, By Procedural Volume Assessment
• 7.2. Diagnostic Procedures*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. SPECT Procedures
  • 7.2.4. PET Procedures
• 7.3. Therapeutic Procedures

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Cardiology*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Oncology
• 8.4. Neurology
• 8.5. Thyroid Disorders
• 8.6. Endocrine Tumors
• 8.7. Lymphoma and Bone Metastasis
• 8.8. Pulmonary Scans
• 8.9. Urology
• 8.10. Others

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Diagnostic Centers
• 9.4. Others

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. GE Healthcare*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Fujifilm (FUJIFILM Toyama Chemical Co. Ltd)
• 11.3. Siemens Healthineers
• 11.4. Bracco
• 11.5. CANON MEDICAL SYSTEMS CORPORATION
• 11.6. Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd)
• 11.7. ATOX CO., Ltd.
• 11.8. IBA Radiopharma Solutions
• 11.9. JFE Engineering Corporation
• 11.10. Koninklijke Philips N.V.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us